Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial

Trial Profile

Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2015

At a glance

  • Drugs Golimumab (Primary)
  • Indications Autoimmune disorders; Ear disorders; Hearing loss; Sensorineural hearing loss
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top